Targeting microRNA to improve diagnostic and therapeutic approaches for malignant mesothelioma

Kimberly A. Birnie; Cecilia M. Prêle; Philip J. Thompson; Bahareh Badrian; Steven E. Mutsaers

doi:10.18632/oncotarget.20409

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

Targeting microRNA to improve diagnostic and therapeutic approaches for malignant mesothelioma

Kimberly A. Birnie, Cecilia M. Prêle, Philip J. Thompson, Bahareh Badrian and Steven E. Mutsaers _

PDF | HTML | How to cite

Oncotarget. 2017; 8:78193-78207. https://doi.org/10.18632/oncotarget.20409

Metrics: PDF 1370 views | HTML 3504 views | ?

Abstract

Kimberly A. Birnie1, Cecilia M. Prêle1,2, Philip J. Thompson1, Bahareh Badrian1 and Steven E. Mutsaers1,2

1Institute for Respiratory Health, Centre for Respiratory Health, Harry Perkins Institute of Medical Research, QEII Medical Centre, School of Biomedical Sciences, University of Western Australia, Perth, Western Australia, Australia

2Centre for Cell Therapy and Regenerative Medicine, Harry Perkins Institute of Medical Research, QEII Medical Centre, School of Biomedical Sciences, University of Western Australia, Perth, Western Australia, Australia

Correspondence to:

Steven E. Mutsaers, email: [email protected]

Keywords: malignant pleural mesothelioma, malignant peritoneal mesothelioma, microRNA, biomarkers, therapies

Received: June 03, 2017 Accepted: August 04, 2017 Published: August 24, 2017

ABSTRACT

Malignant mesothelioma is an aggressive and often fatal cancer associated with asbestos exposure. The disease originates in the mesothelial lining of the serosal cavities, most commonly affecting the pleura. Survival rates are low as diagnosis often occurs at an advanced stage and current treatments are limited. Identifying new diagnostic and therapeutic targets for mesothelioma remains a priority, particularly for the new wave of victims exposed to asbestos through do-it-yourself renovations and in countries where asbestos is still mined and used. Recent advances have demonstrated a biological role for the small but powerful gene regulators microRNA (miRNA) in mesothelioma. A number of potential therapeutic targets have been identified. MiRNA have also become popular as potential biomarkers for mesothelioma due to their stable expression in bodily fluid and tissues. In this review, we highlight the current challenges associated with the diagnosis and treatment of mesothelioma and discuss how targeting miRNA may improve diagnostic, prognostic and therapeutic approaches.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 20409

Publication Alerts

Reviews:

Targeting microRNA to improve diagnostic and therapeutic approaches for malignant mesothelioma

Abstract